文献速递乳腺癌

PALLAS研究中哌柏西利联合辅助内分泌治疗激素受体阳性/HER2阴性早期乳腺癌的暴露与停药分析

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
PubMed 文献 · J Clin Oncol · 2022-01-07

PALLAS研究比较哌柏西利联合辅助内分泌治疗与单用内分泌治疗在II-III期HR+/HER2-早期乳腺癌中的疗效。2840例启动哌柏西利治疗的患者中1199例(42.2%)在2年内停药,多数(772例,27.2%)因不良反应停药,最常见为中性粒细胞减少和疲乏。分析提示两组间iDFS无显著差异与哌柏西利暴露不足不直接相关,加权符合方案分析中哌柏西利组iDFS无改善(HR 0.89;95%CI 0.72-1.11)。

要点

  • 2840例启动哌柏西利治疗的患者中1199例(42.2%)在2年内停药,772例(27.2%)因不良反应停药,最常见为中性粒细胞减少和疲乏。
  • 哌柏西利用药时长更长或暴露强度≥70%与iDFS改善无显著关系。
  • 加权符合方案分析中,哌柏西利组与未用哌柏西利组相比iDFS无改善(HR 0.89;95%CI 0.72-1.11)。

核心结论

  • 尽管PALLAS研究观察到停药率,分析提示两组间iDFS无显著差异与哌柏西利暴露不足不直接相关。
  • 停药率说明引入新型辅助治疗面临的挑战,需要干预措施提高口服抗癌治疗的持续性。

研究设计与样本

  • PALLAS研究将II-III期HR+/HER2-乳腺癌患者随机分配至2年哌柏西利联合辅助内分泌治疗组或单用内分泌治疗组。
  • 主要目标为比较两组的iDFS。
  • 对毒性、剂量调整和早期停药进行持续监测。
  • 采用多变量竞争风险模型分析基线协变量与哌柏西利减量和停药时间的关系。
  • 进行界标分析和逆概率加权符合方案分析评估药物持续性和暴露对iDFS的影响。

主要发现

  • 分析人群共5743例,其中2840例启动哌柏西利治疗;1199例(42.2%)在2年内停用哌柏西利。
  • 停药原因多数为不良反应(772例,27.2%),最常见为中性粒细胞减少和疲乏。
  • 两臂间内分泌治疗停药无差异。
  • 非方案定义原因的停药在哌柏西利治疗前3个月和入组第一个日历年较多,随时间下降。
  • 哌柏西利用药时长更长或暴露强度≥70%与iDFS改善无显著关系。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In this analysis, we evaluated palbociclib exposure and discontinuation in PALLAS. METHODS: Patients with stage II-III HR+, HER2- disease were randomly assigned to 2 years of palbociclib with adjuvant ET versus ET alone. The primary objective was to compare iDFS between arms. Continuous monitoring of toxicity, dose modifications, and early discontinuation was performed. Association of baseline covariates with time to palbociclib reduction and discontinuation was analyzed with multivariable competing risk models. Landmark and inverse probability weighted per-protocol analyses were performed to assess the impact of drug persistence and exposure on iDFS. RESULTS: Of the 5,743 patient analysis population (2,840 initiating palbociclib), 1,199 (42.2%) stopped palbociclib before 2 years, the majority (772, 27.2%) for adverse effects, most commonly neutropenia and fatigue. Discontinuation of ET did not differ between arms. Discontinuations for non-protocol-defined reasons were greater in the first 3 months of palbociclib, and in the first calendar year of accrual, and declined over time. No significant relationship was seen between longer palbociclib duration or ≥ 70% exposure intensity and improved iDFS. In the weighted per-protocol analysis, no improvement in iDFS was observed in patients receiving palbociclib versus not (hazard ratio 0.89; 95% CI, 0.72 to 1.11). CONCLUSION: Despite observed rates of discontinuation in PALLAS, analyses suggest that the lack of significant iDFS difference between arms was not directly related to inadequate palbociclib exposure. However, the discontinuation rate illustrates the challenge of introducing novel adjuvant treatments, and the need for interventions to improve persistence with oral cancer therapies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mayer EL, Fesl C, Hlauschek D, et al. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol. 2022. PMID: 34995105. doi:10.1200/JCO.21.01918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。